Association of metabolic syndrome and inflammation with neurocognition in patients with schizophrenia

Psychiatry Research

Volumn 210, Issue 2, 2013, Pages 381-386

  Boyer, Laurent ^a   Richieri, Raphaëlle ^b   Dassa, Daniel ^c   Boucekine, Mohamed ^a   Fernandez, Jessica ^a   Vaillant, Florence ^b   Padovani, Romain ^b   Auquier, Pascal ^a   Lancon, Christophe ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c La Conception University Hospital ^*  (France)

Author keywords

Inflammation; Metabolic Syndrome; Neurocognition; Schizophrenia

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ALCOHOL ABUSE; ALTERNATIVE MEDICINE; ANTHROPOMETRY; ARTICLE; BLOOD ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DSM-IV; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE LINEAR REGRESSION ANALYSIS; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; COGNITION DISORDERS; COMPLICATION; DRINKING BEHAVIOR; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; OUTPATIENT; PSYCHOLOGY; REGRESSION ANALYSIS; RISK FACTOR; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

ADULT; ALCOHOL DRINKING; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; OUTPATIENTS; PREVALENCE; REGRESSION ANALYSIS; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; SOCIOECONOMIC FACTORS;

EID: 84886951974     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.06.020     Document Type: Article

References (46)

1. Adachi H., Yanai H., Hirowatari Y. The underlying mechanisms for olanzapine-induced hypertriglyceridemia. Journal of Clinical Medicine Research 2012, 4:206-208.
2. Addington D., Addington J., Maticka-Tyndale E. Assessing depression in schizophrenia: the calgary depression scale. British Journal of Psychiatry 1993, 39-44.
3. Amitai N., Markou A. Chronic nicotine improves cognitive performance in a test of attention but does not attenuate cognitive disruption induced by repeated phencyclidine administration. Psychopharmacology (Berlin) 2009, 202:275-286.
4. APA Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC, (text revised). 4th ed.
5. Bowie C.R., Serper M.R., Riggio S., Harvey P.D. Neurocognition, symptomatology, and functional skills in older alcohol-abusing schizophrenia patients. Schizophrenia Bulletin 2005, 31:175-182.
6. Bray G.A. Obesity is a chronic, relapsing neurochemical disease. International Journal of Obesity and Related Metabolic Disorders 2004, 28:34-38.
7. Cheng A., Braunstein J.B., Dennison C., Nass C., Blumenthal R.S. Reducing global risk for cardiovascular disease: using lifestyle changes and pharmacotherapy. Clinical Cardiology 2002, 25:205-212.
8. Citrome L., Holt R.I., Dinan T.G. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al. Diabetes Care 2006, 29:176. author reply 177-178.
9. D'Souza M.S., Markou A. Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmacology 2012, 62:1564-1573.
10. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophrenia Research 2007, 93:261-265.
11. Dik M.G., Jonker C., Comijs H.C., Deeg D.J., Kok A., Yaffe K., Penninx B.W. Contribution of metabolic syndrome components to cognition in older individuals. Diabetes Care 2007, 30:2655-2660.
12. Drake R.E., Essock S.M., Shaner A., Carey K.B., Minkoff K., Kola L., Lynde D., Osher F.C., Clark R.E., Rickards L. Implementing dual diagnosis services for clients with severe mental illness. Psychiatric Services 2001, 52:469-476.
13. Essock S.M., Drake R.E., Burns B.J. A research network to evaluate assertive community treatment: introduction. American Journal of Orthopsychiatry 1998, 68:176-178.
14. Friedman J.I., Wallenstein S., Moshier E., Parrella M., White L., Bowler S., Gottlieb S., Harvey P.D., McGinn T.G., Flanagan L., Davis K.L. The effects of hypertension and body mass index on cognition in schizophrenia. American Journal of Psychiatry 2010, 167:1232-1239.
15. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., Lamberti S., D'Agostino R.B., Stroup T.S., Davis S., Lieberman J.A. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research 2005, 80:45-53.
16. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
17. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. British Journal of Addiction 1991, 86:1119-1127.
18. Holden K.F., Lindquist K., Tylavsky F.A., Rosano C., Harris T.B., Yaffe K. Serum leptin level and cognition in the elderly: findings from the Health ABC study. Neurobiology of Aging 2009, 30:1483-1489.
19. Jurado-Barba R., Morales-Munoz I., Del Manzano B.A., Fernandez-Guinea S., Caballero M., Martinez-Gras I., Rubio-Valladolid G. Relationship between measures of inhibitory processes in patients with schizophrenia: role of substance abuse disorders. Psychiatry Research 2011, 190:187-192.
20. Kahn R., Buse J., Ferrannini E., Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
21. Kassi E., Pervanidou P., Kaltsas G., Chrousos G. Metabolic syndrome: definitions and controversies. BMC Medicine 2011, 9:48.
22. Kay S.R., Opler L.A., Fiszbein A. Significance of positive and negative syndromes in chronic schizophrenia. British Journal of Psychiatry 1986, 149:439-448.
23. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., Salonen J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Journal of the American Medical Association 2002, 288:2709-2716.
24. Leonard B.E., Schwarz M., Myint A.M. The metabolic syndrome in schizophrenia: is inflammation a contributing cause?. Journal of Psychopharmacology 2012, 26:33-41.
25. Li X.L., Aou S., Oomura Y., Hori N., Fukunaga K., Hori T. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 2002, 113:607-615.
26. Lindenmayer J.P., Khan A., Kaushik S., Thanju A., Praveen R., Hoffman L., Cherath L., Valdez G., Wance D. Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophrenia Research 2012, 142:171-176.
27. Liu C.Y., Zhou H.D., Xu Z.Q., Zhang W.W., Li X.Y., Zhao J. Metabolic syndrome and cognitive impairment amongst elderly people in Chinese population: a cross-sectional study. European Journal of Neurology 2009, 16:1022-1027.
28. Manning V., Betteridge S., Wanigaratne S., Best D., Strang J., Gossop M. Cognitive impairment in dual diagnosis inpatients with schizophrenia and alcohol use disorder. Schizophrenia Research 2009, 114:98-104.
29. Meyer J.M., Nasrallah H.A., McEvoy J.P., Goff D.C., Davis S.M., Chakos M., Patel J.K., Keefe R.S., Stroup T.S., Lieberman J.A. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research 2005, 80:9-18.
30. Meyer U., Schwarz M.J., Muller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacology & Therapeutics 2012, 132:96-110.
31. Mitchell A.J., Vancampfort D., Sweers K., van Winkel R., Yu W., De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophrenia Bulletin 2011, 39(2):306-318.
32. Muller N., Schwarz M.J. Immune system and schizophrenia. Current Immunology Reviews 2010, 6:213-220.
33. Nasrallah H.A. Linkage of cognitive impairments with metabolic disorders in schizophrenia. American Journal of Psychiatry 2010, 167:1155-1157.
34. Nawa H., Yamada K. Experimental schizophrenia models in rodents established with inflammatory agents and cytokines. Methods in Molecular Biology 2012, 829:445-451.
35. Olincy A., Harris J.G., Johnson L.L., Pender V., Kongs S., Allensworth D., Ellis J., Zerbe G.O., Leonard S., Stevens K.E., Stevens J.O., Martin L., Adler L.E., Soti F., Kem W.R., Freedman R. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Archives of General Psychiatry 2006, 63:630-638.
36. Oomura Y., Hori N., Shiraishi T., Fukunaga K., Takeda H., Tsuji M., Matsumiya T., Ishibashi M., Aou S., Li X.L., Kohno D., Uramura K., Sougawa H., Yada T., Wayner M.J., Sasaki K. Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats. Peptides 2006, 27:2738-2749.
37. Picciotto M.R., Zoli M. Nicotinic receptors in aging and dementia. Journal of Neurobiology 2002, 53:641-655.
38. Reitz C., Tang M.X., Manly J., Mayeux R., Luchsinger J.A. Hypertension and the risk of mild cognitive impairment. Archives of Neurology 2007, 64:1734-1740.
39. Sommer I.E., de Witte L., Begemann M., Kahn R.S. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? a meta-analysis. Journal of Clinical Psychiatry 2012, 73:414-419.
40. Szoke A., Meary A., Ferchiou A., Trandafir A., Leboyer M., Schurhoff F. Correlations between cognitive performances and psychotic or schizotypal dimensions. European Psychiatry 2009, 24:244-250.
41. Szoke A., Trandafir A., Dupont M.E., Meary A., Schurhoff F., Leboyer M. Longitudinal studies of cognition in schizophrenia: meta-analysis. British Journal of Psychiatry 2008, 192:248-257.
42. van den Berg E., Kloppenborg R.P., Kessels R.P., Kappelle L.J., Biessels G.J. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochimica et Biophysica Acta 2009, 1792:470-481.
43. Whitmer R.A., Sidney S., Selby J., Johnston S.C., Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005, 64:277-281.
44. Wijndaele K., Beunen G., Duvigneaud N., Matton L., Duquet W., Thomis M., Lefevre J., Philippaerts R.M. A continuous metabolic syndrome risk score: utility for epidemiological analyses. Diabetes Care 2006, 29:2329.
45. Wing V.C., Wass C.E., Soh D.W., George T.P. A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Annals of the New York Academy of Sciences 2012, 1248:89-106.
46. Yaffe K., Kanaya A., Lindquist K., Simonsick E.M., Harris T., Shorr R.I., Tylavsky F.A., Newman A.B. The metabolic syndrome, inflammation, and risk of cognitive decline. Journal of the American Medical Association 2004, 292:2237-2242.